HBOT for Wound Healing: What the Evidence Actually Shows

If there is one area where the evidence for hyperbaric oxygen therapy is most firmly established, it is wound healing. While HBOT attracts considerable debate in other applications, its role in treating certain chronic and complex wounds has been validated through decades of clinical research and is recognised by major medical bodies worldwide.

Understanding what the evidence actually supports, and where its limits lie, is essential before pursuing treatment or referring a patient.

Why Oxygen Matters for Wound Healing

Wound healing is an oxygen-dependent process. Tissue repair requires oxygen for collagen synthesis, immune cell function, and the formation of new blood vessels. When a wound fails to heal, inadequate oxygen delivery to the wound bed is frequently a contributing factor.

Hyperbaric oxygen therapy addresses this directly. By breathing pure oxygen at pressures above atmospheric, the amount of oxygen dissolved in blood plasma increases substantially, reaching tissues that compromised circulation cannot adequately supply. At 2.0 to 2.5 ATA, plasma oxygen levels can rise to fifteen or twenty times their normal value.

This elevated oxygen concentration supports several mechanisms relevant to wound healing: it stimulates angiogenesis (the growth of new blood vessels), enhances the bactericidal activity of white blood cells, reduces oedema, and promotes the proliferation of fibroblasts, the cells responsible for producing collagen and rebuilding tissue architecture.

The Wounds That Respond Best

Not all wounds are equally responsive to HBOT. The evidence is strongest for specific categories where hypoxia, insufficient oxygen at the tissue level, is a primary driver of non-healing.

Diabetic foot ulcers represent the most extensively studied application. Peripheral arterial disease and neuropathy in diabetic patients create conditions where wounds on the feet and lower limbs fail to progress through normal healing stages. Multiple randomised controlled trials and systematic reviews have demonstrated that adjunctive HBOT reduces the risk of major amputation and improves healing rates in patients with Wagner Grade 3 or higher diabetic foot ulcers.

Radiation tissue damage is another well-supported indication. Radiation therapy can cause progressive damage to blood vessels in treated tissue, a condition called osteoradionecrosis when it affects bone, and radiation-induced soft tissue necrosis in other areas. HBOT is used both to treat established radiation damage and, in some protocols, to prepare tissue for reconstructive surgery following radiation.

Compromised flaps and grafts, surgical tissue transfers that are failing due to inadequate perfusion, can sometimes be salvaged with HBOT when initiated promptly. The window for intervention is narrow, and access to a chamber quickly matters.

Chronic refractory osteomyelitis, bone infection that has not responded to standard antibiotic treatment, is another recognised indication, where the combination of elevated oxygen and enhanced immune function can support resolution of infection.

What the Protocols Look Like

For wound healing indications, HBOT is almost always delivered in a hard shell chamber at pressures of 2.0 to 2.5 ATA. Sessions typically last 90 minutes, and a standard course of treatment involves 20 to 40 sessions, often delivered daily on weekdays.

This is not a brief intervention. A full course of treatment represents a significant time commitment, typically four to eight weeks, and is most effective when integrated with comprehensive wound care that addresses the underlying causes of non-healing alongside the HBOT.

The clinical decisions about pressure, duration, and number of sessions belong to the treating physician. Protocols are calibrated to the specific wound type, the patient's overall condition, and their response to treatment. What works for a diabetic foot ulcer may differ from what is appropriate for radiation tissue damage.

What HBOT Does Not Do

It is worth being direct about the limits of the evidence.

HBOT is not a standalone wound treatment. It is adjunctive, meaning it works alongside, not instead of, appropriate wound care, infection management, vascular assessment, and where relevant, surgical intervention. A wound that has not been properly debrided, or where arterial insufficiency has not been addressed, will not respond to HBOT alone.

HBOT is also not appropriate for all chronic wounds. Venous leg ulcers, for example, have a different pathophysiology, the primary problem is venous hypertension rather than tissue hypoxia, and the evidence for HBOT in this context is considerably weaker.

Patient selection matters enormously. The wounds that respond best to HBOT are those where tissue hypoxia is a significant contributor to non-healing and where the patient's overall condition allows them to tolerate a pressurised environment safely. A thorough assessment before committing to a course of treatment is not optional, it is the foundation of a good outcome.

Accessing Treatment

Hard shell HBOT for wound healing is available through hospital-based hyperbaric units, specialist wound care centres, and private hyperbaric clinics. The availability and cost of treatment varies considerably by location.

In the United States, Medicare covers HBOT for certain diabetic foot ulcer and radiation tissue damage indications when specific clinical criteria are met. Private insurance coverage varies by policy and insurer. In many other markets, access is typically through private specialist centres.

For patients travelling internationally to access treatment, whether for cost reasons, availability, or the quality of a specific facility, understanding the clinical requirements and logistics in advance makes a significant difference. A course of 30 or 40 daily sessions is a substantial commitment, and arriving at a clinic without a clear plan for the full course is a common and avoidable problem.

A Note on Coordination

Wound healing HBOT works best when the hyperbaric physician is in communication with the rest of the treating team, the vascular surgeon, the endocrinologist, the wound care nurse. Fragmented care, where HBOT is pursued in isolation from the broader wound management plan, produces worse outcomes than integrated treatment.

If you are navigating access to HBOT for wound healing, whether for yourself, a family member, or a patient, understanding the full picture before you begin is worth the time. The right clinic, the right protocol, and the right coordination with existing care are not details to sort out after treatment has started.